SR ONE CAPITAL MANAGEMENT, LP 13F Portfolio
SR ONE CAPITAL MANAGEMENT, LP runs SR ONE CAPITAL MANAGEMENT, LP and currently holds 15 stock positions, which is fewer than the average of 231 among the investors we track. The portfolio is valued at approximately $1.04B. Their top holdings are MANE, ZBIO, CRSP, AVLN, DSGN. The top five represent 71.0% of reported portfolio weight. SR ONE CAPITAL MANAGEMENT, LP ranks #174 out of 1000 investors tracked by Alpha Score. In the most recent quarter, SR ONE CAPITAL MANAGEMENT, LP initiated 1 new position. They added to 1 existing position. Their current best-performing preview position is MANE with returns of +94.68%.
Portfolio Value
$1.04B
Alpha Score
97.5
#174 of 1000
Holdings
15
SR ONE CAPITAL MANAGEMENT, LP Current 13F Holdings
Reported holdings from SR ONE CAPITAL MANAGEMENT, LP's latest SEC 13F filing, ranked by portfolio weight.
15 stock holdings
| Holding | Weight | Avg Buy | Current | Return | Quarter Change |
|---|---|---|---|---|---|
 MANE Veradermics, Inc. | 28.42% | $63.15 | $130.65 | +106.89% | Held |
 ZBIO Zenas BioPharma, Inc | 12.31% | $17.41 | $27.26 | +56.58% | Held |
 CRSP CRISPR Therapeutics AG | 10.70% | $66.54 | $53.39 | -19.76% | Held |
AV AVLN Avalyn Pharma, Inc | 10.48% | $32.92 | $25.76 | -21.75% | New Buy |
 DSGN Design Therapeutics, Inc. | 9.09% | $19.87 | $11.65 | -41.37% | Held |
 ALMS Alumis Inc. | 5.31% | $12.54 | $7.16 | -42.90% | Held |
 ORIC ORIC Pharmaceuticals, Inc. | 4.81% | $10.16 | $11.99 | +18.01% | Added +2.23% |
 MLYS Mineralys Therapeutics Inc. | 4.06% | $15.55 | $23.37 | +50.29% | Held |
 SPRY ARS Pharmaceuticals, Inc. | 3.09% | $8.02 | $4.23 | -47.26% | Held |
 RARE Ultragenyx Pharmaceutical Inc. | 0.44% | $23.00 | $15.48 | -32.70% | Held |
Showing 1-10 of 15